| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Original Article |
Departments of Laboratory Medicine and Pathology (R.V.), Medicine, Pediatrics, and Otolaryngology, (P.G.W.), University of Toronto, and Departments of Pathology and Laboratory Medicine (R.V.) and Medicine and Endocrine Oncology Program (P.G.W.), Mount Sinai Hospital, Toronto M5G 1X5, Canada
Address all correspondence and requests for reprints to: Dr. Reinhold Vieth, Pathology and Laboratory Medicine, Mount Sinai Hospital, 600 University Avenue, Toronto, Ontario M5G 1X5, Canada. E-mail: rvieth{at}mtsinai.on.ca.
| Abstract |
|---|
|
|
|---|
| Introduction |
|---|
|
|
|---|
Many reports show an inverse correlation between PTH and 25(OH)D for the elderly (6, 7, 8, 9, 10), and although the same phenomenon is true for young adults (11) and adolescents (12), there have been no systematic comparisons of this relationship across age groups.
Several reports have assumed that the decay function for PTH vs. 25(OH)D must reach a plateau and concluded this plateau occurs when 25(OH)D concentration is at least 72 nmol/liter (4, 6, 7, 9, 10). We are not aware that the assumption of a plateau relationship is consistently valid or similar for all age groups.
To address these issues, we analyzed laboratory data from a cross-section of thyroid clinic outpatients who had been evaluated for vitamin D and parathyroid status as part of their routine follow-up visits. The aims were to determine whether the relationships among 25(OH)D concentration, vitamin D intake, and PTH concentration differ among adult age groups. We will show that for similar 25(OH)D concentrations, PTH concentrations are consistently higher in the elderly than in younger adults. Our data also support the need for higher intake of vitamin D in older adults, not because they are less efficient at maintaining 25(OH)D concentrations, but because they need higher 25(OH)D concentrations to prevent secondary hyperparathyroidism.
| Subjects and Methods |
|---|
|
|
|---|
Subjects were euthyroid outpatients who were being treated for various thyroid conditions, as presented in Table 1
. The analyses were done because their endocrinologist (P.G.W.) regarded them as relevant to his routine surveillance of his patients endocrine and nutritional health; furthermore, our laboratory is a regional referral laboratory for the vitamin D analyses, and the incremental cost was marginal. The hospitals ethics review committee approved this descriptive study. Data for patients assessed for serum PTH, 25(OH)D, 1,25-hydroxyvitamin D [1,25(OH)2D], and biochemical parameters related to calcium metabolism were captured, using a structured query, from the hospitals computer database system for laboratory data and patient demographics (SoftLab, Boca Raton, FL). We limited the data assembled for the present report to a time window during which our laboratory made no modifications to the pertinent methods. In total, the study included biochemical data from 1741 adult endocrine outpatients who were not suffering from parathyroid or calcium-related disease based on biochemical measures and clinical assessment (12 patients had been removed from the data set because of serum calcium >2.7 mmol/liter). Data were collected from patient visits between May 1997 and the end of December 1998; of these, 1049 (60%) of 1741 samples were obtained during the summer half of the year, May through October inclusive, when sunshine at our latitude (42 degrees north) increases 25(OH)D concentrations (11). Of the 568 consecutive patient charts reviewed, we had recorded vitamin D intake in a subset of 531 consecutive based on intake of mineral and vitamin supplements reported by the patients. Focus on patients seen in spring and summer was used to increase the proportion of elderly in this subset. Patients who previously had low 25(OH)D (<50 nmol/liter) had been advised to take vitamin D3, as 25-µg (1000 IU) pills available over the counter.
|
We measured the intact PTH molecule, as implemented on the DPC Immulite 2000 (DPC, Los Angeles, CA). Serum 25(OH)D was measured with a RIA (DiaSorin, Inc., Stillwater, MN) with which our laboratory consistently reported close to the mean of the DEQAS international proficiency survey for this analyte (13). Serum 1,25(OH)2D was measured with the classic, calf-thymus receptor assay, involving purification of analyte on Bond Elut C18OH cartridges (Varian, Harbor City, CA) and an internal standard to correct for losses during purification (14).
Statistical analysis and graphical presentation were carried out using SPSS version 10 (SPSS, Inc., Chicago, IL). Analysis was based on data available through clinical practice, and because of this, there are variations in sample size, as we note throughout this report. The locally weighted regression and scatterplot smoothing (LOWESS) technique was applied to allow the graphed data to reveal their own patterns (15); LOWESS is available as part of the SPSS software. The exponential decay function was determined by Dr. K. Norwich (Department of Biomedical Engineering, University of Toronto), fitting of the data to three parameters of an exponential decay equation, using iterative regression analysis to optimize the fit.
| Results |
|---|
|
|
|---|
Comparisons of 25(OH)D concentration, vitamin D intake, and age group showed distinct increases in serum 25(OH)D with higher vitamin D intake. However, there was none of the expected evidence that the young exhibit higher 25(OH)D concentrations than older adults when consuming similar amounts of vitamin D (Fig. 1
). Among the 404 patients who were not taking vitamin supplements based on what they reported to us, there was no relationship between age group and serum 25(OH)D concentration, based on one-way ANOVA (P > 0.4). The median 25(OH)D concentration associated with each level of vitamin D intake was actually higher for the oldest age group than the younger groups, but in each case this was not statistically significant. Because the bottom of each box in the figure indicates the 25th percentile, the figure shows that for adults who do not take vitamin D supplements, the prevalence of vitamin D insufficiency is about 25%, regardless of age. Figure 1
also shows that for patients reporting vitamin D intake of at least 800-1000 IU/d, there is reasonable assurance (based on the bottom whisker of the box plots) that 25(OH)D concentration exceed 40 nmol/liter.
|
![]() |
With this approach, the PTH concentration approached a theoretical low plateau at 25(OH)D concentrations more than 73 nmol/liter (Fig. 2
). However, application of the LOWESS plot to the same data revealed a substantial divergence of the data (based on natural shape) from the exponential plot of the above equation (based on investigator expectation of a plateau).
|
|
|
|
|
| Discussion |
|---|
|
|
|---|
Cleveland (15) developed the locally weighted scatterplot smoother line (LOWESS) to offer investigators a way to determine what he regarded as the true shape of scatterplot relationships without an investigator-driven bias. We found that regression lines obtained using log PTH vs. log 25(OH)D concentrations were a close match to LOWESS plots of the data, indicating that for our subjects, there was no evidence of a plateau relationship.
There are several possible explanations for why we saw a different quality of 25(OH)D vs. PTH relationship than what others have reported. Differences in the biochemical test methods used, the sample population tested, and investigator expectations could all play a role. The lack of a 25(OH)D-related plateau in PTH concentrations was consistently seen in all three age groups, based on both the regression (Fig. 3
) and progressive declines in mean PTH concentrations whenever 25(OH)D was higher (Fig. 4
). We think that the lack of a PTH plateau would also apply to patients without thyroid disease because extremely high 25(OH)D concentrations are known to cause severe suppression of PTH in normal subjects (16), and high vitamin D doses can be used to treat hypoparathyroidism without a requirement for PTH therapy. Although it cannot be excluded that the present results are unique to this patient cohort, all of these patients were euthyroid when these biochemical tests were ordered and very probably not different from what would have been observed if we had access to similar data for healthy volunteers. Use of volunteer subjects would also have been a selective sampling, and such an approach would have yielded a smaller proportion of elderly subjects.
If there is no plateau in the relationship between PTH vs. 25(OH)D, then the choice of an optimal or desirable 25(OH)D concentration, based only on PTH, becomes arbitrary. If lower PTH is a goal, then a higher 25(OH)D concentration will always lower PTH further.
PTH concentrations were consistently highest in the oldest adults, for whom it declined more gradually than in the young, as 25(OH)D increased. This is reminiscent of the relative resistance to 1,25(OH)2D previously reported for the elderly (17).
It is often assumed that there is a positive relationship between the circulating concentrations of the theoretically inactive compound, 25(OH)D, and 1,25(OH)2D. This is as if to say consumption of vitamin D is equivalent to providing a higher circulating 1,25(OH)2D concentration. Need et al. (18) emphasized that a 25(OH)D concentration of 40 nmol/liter was important because above this cut-point the concentration of 1,25(OH)2D increased along with rising 25(OH)D concentrations. Likewise, Devine et al. (19) reported that in elderly women, there is a strong positive correlation between 25(OH)D and 1,25(OH)2D. Our results did not confirm this aspect of either of those reports. No matter how we analyzed our data, they exhibited no association or cut-point between 25(OH)D and concentrations of 1,25(OH)2D (Fig. 5
). In the rat, there is a strong negative relationship between 25(OH)D and 1,25(OH)2D concentrations (20), so it makes little sense to us why the opposite should occur in man. We suggest that reports showing a positive correlation between these metabolites in man reflect either a selective focus on a subset of results to confirm an expectation (18) or interference in the 1,25(OH)2D assay by another metabolite (19). Hollis (21), originator of the 1,25(OH)2D method used by Devine et al. (19), showed that the method was interfered with by 24,25(OH)2D (a metabolite whose levels parallel those of 25(OH)D). Therefore, he adopted the modifications included in the 1,25(OH)2D method we used for the present work (14). Our findings confirm those of Barger-Lux et al. (22) showing that 25(OH)D concentrations in healthy adults do not affect circulating 1,25(OH)2D.
If it is not through circulating 1,25(OH)2D, then by what mechanism does 25(OH)D suppress PTH? The parathyroid gland does possess vitamin D receptor (23, 24), and recently Segersten et al. (25) demonstrated expression of 25(OH)D-1-
-hydroxylase in human parathyroid tissue by RT-PCR and immunohistochemical analysis. Therefore, circulating 25(OH)D can affect PTH secretion and parathyroid growth by 1,25 (OH)2D generated within parathyroid tissue. 25(OH)D is not a hormone, but it serves as the substrate required for normal, paracrine control of parathyroid tissue.
The authors of the Food and Nutrition Board guidelines for calcium and related nutrients suggested that because cutaneous vitamin D production in the elderly is diminished (26), the elderly require more vitamin D intake to compensate for that (1). Therefore, one should expect that for adults who do not take supplementary vitamin D, the elderly group should have lower 25(OH)D concentrations than younger adults. However, in agreement with other published reports that have compared 25(OH)D levels among age groups (27, 28, 29), the 25(OH)D concentrations in the elderly patients were certainly not lower than those in the younger ones. The paradox for the elderly is that although cutaneous vitamin D production is diminished (26), 25(OH)D concentrations are not affected. This can be explained by the age-related decline in kidney function. As kidney function declines in rats, so does 1,25(OH)2D production (30) and metabolic clearance of 25(OH)D. Likewise, the most consistent relationship that we saw across adult age groups was that 1,25(OH)2D correlated inversely with creatinine (Table 2
). Thus, although vitamin D production in the skin decreases with age, so does the utilization of 25(OH)D in the kidney; these effects cancel each other out so that aging per se has no effect on 25(OH)D levels. This interpretation is suggested by our results, but because we are not aware of any studies reporting on the effect of age on biological turnover of 25(OH)D, more conclusive studies are needed. The effect of age was complex, and the quality of several relationships changed with the age group being analyzed. In particular, the relationship between diminishing kidney function and increasing PTH became stronger with each older age group, as did the relationship between creatinine and age itself. These observations show that the age-related differences among these relationships cannot be explained on the basis of vitamin D nutrition alone. It appears that the elderly become somewhat resistant to the effects of 25(OH)D in a manner reminiscent of the relative resistance to 1,25(OH)2D previously reported in elderly adults (17).
One issue that remains is whether individuals of all ages require similar 25(OH)D concentrations and vitamin D intakes. We conclude that if the aim of vitamin D supplementation in adults is to suppress PTH, then the elderly need higher intakes because they are resistant to effects of the nutrient. However, if the aim of vitamin D supplementation is to ensure a minimum target level of 25(OH)D, then the daily consumption of vitamin D should be the same for all adults, regardless of age. The present cross-sectional study confirms a previous intervention study (31), showing that if one wants to ensure that all adults have 25(OH)D of at least 40 nmol/liter, they must consume at least 2025 µg (8001000 IU) vitamin D3 daily.
| Acknowledgments |
|---|
| Footnotes |
|---|
Abbreviations: 1,25(OH)2D, 1,25-Hydroxyvitamin D; 25(OH)D, 25-hydroxyvitamin D; AI, adequate intake; LOWESS, locally weighted regression and scatterplot smoothing technique.
Received July 10, 2002.
Accepted October 14, 2002.
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
J R Tucci Vitamin D therapy in patients with primary hyperparathyroidism and hypovitaminosis D Eur. J. Endocrinol., July 1, 2009; 161(1): 189 - 193. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. O. Kuchuk, S. M. F. Pluijm, N. M. van Schoor, C. W. N. Looman, J. H. Smit, and P. Lips Relationships of Serum 25-Hydroxyvitamin D to Bone Mineral Density and Serum Parathyroid Hormone and Markers of Bone Turnover in Older Persons J. Clin. Endocrinol. Metab., April 1, 2009; 94(4): 1244 - 1250. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. M Smith, K. K Gardner, J. Locke, and S. R Zwart Vitamin D supplementation during Antarctic winter Am. J. Clinical Nutrition, April 1, 2009; 89(4): 1092 - 1098. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Eastell, A. Arnold, M. L. Brandi, E. M. Brown, P. D'Amour, D. A. Hanley, D. S. Rao, M. R. Rubin, D. Goltzman, S. J. Silverberg, et al. Diagnosis of Asymptomatic Primary Hyperparathyroidism: Proceedings of the Third International Workshop J. Clin. Endocrinol. Metab., February 1, 2009; 94(2): 340 - 350. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. D Fraser Standardization of vitamin D assays: art or science? Ann Clin Biochem, January 1, 2009; 46(1): 3 - 4. [Full Text] [PDF] |
||||
![]() |
R. M. Yoho, J. Frerichs, N. B. Dodson, R. Greenhagen, and S. Geletta A Comparison of Vitamin D Levels in Nondiabetic and Diabetic Patient Populations J Am Podiatr Med Assoc, January 1, 2009; 99(1): 35 - 41. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Bikle Nonclassic Actions of Vitamin D J. Clin. Endocrinol. Metab., January 1, 2009; 94(1): 26 - 34. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. N. Taylor, C. L. Wagner, and B. W. Hollis Vitamin D Supplementation during Lactation to Support Infant and Mother J. Am. Coll. Nutr., December 1, 2008; 27(6): 690 - 701. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. L. Carter, S. E. O'Riordan, G. L. Eaglestone, M. P. Delaney, and E. J. Lamb Bone mineral metabolism and its relationship to kidney disease in a residential care home population: a cross-sectional study Nephrol. Dial. Transplant., November 1, 2008; 23(11): 3554 - 3565. [Abstract] [Full Text] [PDF] |
||||
![]() |
D.-H. Manicourt and J.-P. Devogelaer Urban Tropospheric Ozone Increases the Prevalence of Vitamin D Deficiency among Belgian Postmenopausal Women with Outdoor Activities during Summer J. Clin. Endocrinol. Metab., October 1, 2008; 93(10): 3893 - 3899. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Prentice, G. R Goldberg, and I. Schoenmakers Vitamin D across the lifecycle: physiology and biomarkers Am. J. Clinical Nutrition, August 1, 2008; 88(2): 500S - 506S. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Misra, D. Pacaud, A. Petryk, P. F. Collett-Solberg, M. Kappy, and on behalf of the Drug and Therapeutics Committee o Vitamin D Deficiency in Children and Its Management: Review of Current Knowledge and Recommendations Pediatrics, August 1, 2008; 122(2): 398 - 417. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. A. Bowden, R. F. Robinson, R. Carr, and J. D. Mahan Prevalence of Vitamin D Deficiency and Insufficiency in Children With Osteopenia or Osteoporosis Referred to a Pediatric Metabolic Bone Clinic Pediatrics, June 1, 2008; 121(6): e1585 - e1590. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Rejnmark, P. Vestergaard, L. Heickendorff, and L. Mosekilde Plasma 1,25(OH)2D levels decrease in postmenopausal women with hypovitaminosis D. Eur. J. Endocrinol., April 1, 2008; 158(4): 571 - 576. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Sahota, H. Barnett, M. Lesosky, J. M. Raboud, R. Vieth, and J. A. Knight Association of Vitamin D Related Information from a Telephone Interview with 25-Hydroxyvitamin D Cancer Epidemiol. Biomarkers Prev., January 1, 2008; 17(1): 232 - 238. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. P Heaney and J. M Lappe Reply to MM Sood and AR Sood Am. J. Clinical Nutrition, November 1, 2007; 86(5): 1549 - 1550. [Full Text] [PDF] |
||||
![]() |
K. E. Ensrud, L.-Y. Lui, B. C. Taylor, A. Ishani, M. G. Shlipak, K. L. Stone, J. A. Cauley, S. A. Jamal, D. M. Antoniucci, S. R. Cummings, et al. Renal Function and Risk of Hip and Vertebral Fractures in Older Women Arch Intern Med, January 22, 2007; 167(2): 133 - 139. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. T. Viljakainen, A. Palssa, M. Karkkainen, J. Jakobsen, and C. Lamberg-Allardt How much vitamin d3 do the elderly need? J. Am. Coll. Nutr., October 1, 2006; 25(5): 429 - 435. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. F Aloia, S. A Talwar, S. Pollack, M. Feuerman, and J. K Yeh Optimal vitamin D status and serum parathyroid hormone concentrations in African American women. Am. J. Clinical Nutrition, September 1, 2006; 84(3): 602 - 609. [Abstract] [Full Text] [PDF] |
||||
![]() |
R.M. Francis, F.H. Anderson, S. Patel, O. Sahota, and T.P. van Staa Calcium and vitamin D in the prevention of osteoporotic fractures QJM, June 1, 2006; 99(6): 355 - 363. [Full Text] [PDF] |
||||
![]() |
D. Maggio, A. Cherubini, F. Lauretani, R. C. Russo, B. Bartali, M. Pierandrei, C. Ruggiero, M. C. Macchiarulo, R. Giorgino, S. Minisola, et al. 25(OH)D Serum Levels Decline With Age Earlier in Women Than in Men and Less Efficiently Prevent Compensatory Hyperparathyroidism in Older Adults J. Gerontol. A Biol. Sci. Med. Sci., November 1, 2005; 60(11): 1414 - 1419. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Gaugris, R.P. Heaney, S. Boonen, H. Kurth, J.D. Bentkover, and S.S. Sen Vitamin D inadequacy among post-menopausal women: a systematic review QJM, September 1, 2005; 98(9): 667 - 676. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Vieth, D. E.C. Cole, J. H. Krege, D. W. Donley, R. Marcus, and A. A. Licata Teriparatide, Osteoporosis, Calcium, and Vitamin D N. Engl. J. Med., August 11, 2005; 353(6): 634 - 635. [Full Text] [PDF] |
||||
![]() |
B.E. C. Nordin and A. G. Need The Relation Between Serum Calcidiol and Calcitriol IBMS BoneKEy, May 1, 2005; 2(5): 7 - 16. [Full Text] [PDF] |
||||
![]() |
R. Vieth, R. Scragg, P.E. Norman, and J.T. Powell Vitamin D Nutrition Does Not Cause Peripheral Artery Disease Arterioscler. Thromb. Vasc. Biol., May 1, 2005; 25(5): e41 - e42. [Full Text] [PDF] |
||||
![]() |
B. W. Hollis Circulating 25-Hydroxyvitamin D Levels Indicative of Vitamin D Sufficiency: Implications for Establishing a New Effective Dietary Intake Recommendation for Vitamin D J. Nutr., February 1, 2005; 135(2): 317 - 322. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. C Fleet Genomic and proteomic approaches for probing the role of vitamin D in health Am. J. Clinical Nutrition, December 1, 2004; 80(6): 1730S - 1734S. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. M Weaver and J. C Fleet Vitamin D requirements: current and future Am. J. Clinical Nutrition, December 1, 2004; 80(6): 1735S - 1739S. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. G. Need, P. D. O'Loughlin, H. A. Morris, M. Horowitz, and B. E. C. Nordin The Effects of Age and Other Variables on Serum Parathyroid Hormone in Postmenopausal Women Attending an Osteoporosis Center J. Clin. Endocrinol. Metab., April 1, 2004; 89(4): 1646 - 1649. [Abstract] [Full Text] [PDF] |
||||
![]() |
V.-V. Valimaki, H. Alfthan, E. Lehmuskallio, E. Loyttyniemi, T. Sahi, U.-H. Stenman, H. Suominen, and M. J. Valimaki Vitamin D Status as a Determinant of Peak Bone Mass in Young Finnish Men J. Clin. Endocrinol. Metab., January 1, 2004; 89(1): 76 - 80. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. M. Weaver 2003 W. O. Atwater Memorial Lecture: Defining Nutrient Requirements from a Perspective of Bone-Related Nutrients J. Nutr., December 1, 2003; 133(12): 4063 - 4066. [Full Text] [PDF] |
||||
![]() |
M. F. Holick The Parathyroid Hormone D-Lema J. Clin. Endocrinol. Metab., August 1, 2003; 88(8): 3499 - 3500. [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |